AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

Source: 
Endpoints
snippet: 

The crown jewel of AbbVie’s big-dollar acquisition of Allergan, Botox is one of the most recognizable brands in pharma — and both drugmakers have worked overtime to protect its advantage. After scoring a fatal blow to Evolus’ chances at a major competitor late last year, AbbVie is now putting the icing on the cake.